With a response rate of over 90%, the researcher is leading the first multiple myeloma study in humans.

Published Date: 19 Apr 2023

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center was the principal site for a promising first-in-human clinical trial for people with relapsed multiple myeloma. Patients who received higher doses of.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

2.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

3.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

4.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

5.

Telehealth in the pandemic era resulted in fewer therapy interruptions.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot